Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by a reciprocal translocation of long arms of chromosomes 9 and 22 (Philadelphia chromosome). Since the approval of Imatinib in 2001, Dasatinib and Nilotinib have been approved for use in Imatinib resistant or intolerant as well as front line treatment for CML cases. The most common side effects of these kinase inhibitors include myelosuppression, nausea, vomiting, diarrhea, mild skin rash, and Q Tc prolongation, but serious allergic reactions are rare. Here, we present a case series of Nilotinib induced dermatologic toxicities.
The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We use cookies and other tracking technologies to work properly, to analyze our website traffic, and to understand where our visitors are coming from. More InfoGot It!
